Switzerland Archives

karolinska microbiome ferring pharma research scilifelab

News and Trends 28 Jan 2016

Sweden and Switzerland Join in on Microbiome Hype with New Karolinska Research Centre

Ferring Pharmaceuticals (Switzerland) and the Karolinska Institutet (Sweden) announce a collaboration on a new research centere exploiting the human microbiome. The Karolinska Institutet has a deep understanding of the human microbiome, and the institute actually accounts for over 40% of the medical academic research conducted in Sweden (not to mention their long-standing ties with the Nobel Prize […]

January 28, 2016 - 2 minutesmins - By Dani Bancroft

kuros cytos biotechnologies biosciences vaccine hepatitis merger bone biosurgeries

News and Trends 20 Jan 2016

Swiss Biotech Merger: Bones + Oncology + Vaccines?

Kuros Biosurgery in Zürich (Switzerland), the bone remodelling biotech for trauma patients, today officially acquired Cytos Biotechnology in Schlieren, the two of which are now to be rebranded ‘Kuros Biosciences’ in a Swiss Stock Exchange merger. Kuros is developing innovative products for tissue repair and regeneration. The company is a spin-off of the Swiss Federal […]

January 20, 2016 - 2 minutesmins - By Dani Bancroft

macular degeneration xbrane helvetic xlucane biosimilar lucentis blindness iran

News and Trends 18 Jan 2016

Where there be Patent-Free Markets: Swiss-Swedish Biosimilar for Blindess Reaches Iran

Helvetic BioPharma (Switzerland) estimates that 70,000 people suffer from age-related macular degeneration in Iran, the leading cause of blindness. This deal with Xbrane in Stockholm (Sweden) will debut a biosimilar therapy that could really tackle this problem. Xbrane itself is a Swedish biopharma with links to Italy (after an acquisition of the Italian Primm Pharma […]

January 18, 2016 - 2 minutesmins - By Dani Bancroft

clostridium difficile microbiomics seres health therapeutics nestle science crohns ibd uc cdi

News and Trends 12 Jan 2016

Microbiomics and Nestlé: €1.7Bn for New TransAtlantic Drug Development Program

Microbiomics is a hot area for biotech. Now US Seres Therapeutics and Nestlé Health Sciences have signed a massive drug development deal for bowel diseases and C.difficile infections. By correcting the fundamental microbiome dysbiosis that is the root cause of many diseases, Seres Theraputics in Cambridge (US) is creating a profoundly new and important way […]

January 12, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 8 Jan 2016

BioArt in Berlin: Making Dystopia Beautiful with Prostheses and the Transhuman Life

I met the curators of a BioArt Gallery in Berlin very recently and they invited me to their latest of exhibition ‘Prostheses: Transhuman Life’ by the Artist Susanna Hertrich. The exhibition, hosted by Christian De Lutz and Regine Rapp (the wonderfully warm curators of Art Laboratory Berlin) presented ‘wearable tech’ devices made to trigger emotions, […]

January 8, 2016 - 4 minutesmins - By Dani Bancroft

crispr bayer therapeutics genetic disease joint venture london

News and Trends 22 Dec 2015

Serious Genetic Diseases have a New CRISPR Dream Duo Venture worth in Excess of €275M

Blood disorders, blindness and congenital heart disease? The new Bayer Life Science Center (BLSC) in Germany and CRISPR Therapeutics (Switzerland) have now created a joint Venture to tackle cures for these rare genetic defects. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise […]

December 22, 2015 - 2 minutesmins - By Dani Bancroft

hypoxia cancer hpv inthera aglaia oncology

News and Trends 17 Dec 2015

The Assault on Solid Tumors: How ‘Blinding’ Cancer is an Attractive Therapeutic Approach

The Dutch Oncology VC Specialist Aglaia has invested €3.4M in the Swiss Start-Up Inthera Bioscience for their Small molecule platform against solid tumors. Aglaia is a venture capital firm based in Bilthoven (NL) which has 3 funds under their management for specialist investment into Oncology research. Last year they raised over €50M as part of […]

December 17, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 14 Dec 2015

World’s First Microbiome Fund Swells to €160M With Major Pharma Also Chipping In

The French VC firm Seventure‘s Health for Life Capital investment fund for Microbiome and Biotech has had an additional €60M pumped into it by Swiss Pharma Giant Novartis and other investors. Health for Life Capital is the first and unique microbiome focused investment vehicle. Now it has been announced that Novartis and other investors have also become […]

December 14, 2015 - 2 minutesmins - By Dani Bancroft

roche cellsqueeze sqz cell therapies Cancer

News and Trends 9 Dec 2015

Squeezing Cells: A Revolutionary Cancer Drug Delivery Platform for €455M?

The MIT spin-off SQZ Biotech has an invention (Cell SQueeZe) which could make vector drug delivery in Cancer a thing of the past… Roche thinks so too, and has now acquired this small biotech for €455M upfront. MIT Professors Klavs Jensen, Robert Langer and PhD Student Armon Sharei were focused on developing a more effective system for […]

December 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 9 Dec 2015

CAR-T Phase II: 93% Complete Remission in Children with Relapsed Leukemia!

Wow! 55 of 59 patients in a Novartis trial experienced complete remission in one of the largest investigational CAR-T therapies for children with relapsed/refractory acute lymphoblastic leukemia (ALL). These are the latest findings from an ongoing phase II study of CTL019, an investigational chimeric antigen receptor T-cell (CAR-T) therapy, further support its potential in the […]

December 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 7 Dec 2015

Hydra’s Immortality is not Myth: Polyps Genetically Reprogram Skin Cells into Neurons

Relatives of the Jellyfish, researchers at the University of Geneva (Switzerland) have now proven the regenerative abilities of Hydra involved reprogramming cells. Does this have any implications for Neurodegenerative disease? Remember the Greek myth of Hydra? Amongst other twelve labours, Hercules had to slay the nine-headed monster Hydra which, in case nine jaws weren’t enough, […]

December 7, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 4 Dec 2015

Delenex Therapeutics, the Swiss Biotech developing new types of Therapeutic Antibodies

This week we leave the old city of Oxford and travel South East across the channel, through France and arrive at our destination, Zurich, Switzerland. This wonderful city is famous for its many churches (including the Minster), the largest church clock in Europe, found on St Peter’s and is the home of many celebrities including […]

December 4, 2015 - 2 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us